SCHEMBL1050255

SCHEMBL1050255

COCCOc1ccc(F)c(Cc2c[nH]c3ncccc23)c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 2/20 0.49
FGFR1 P11362 1/20 0.45
FGFR4 P22455 1/20 0.45
MET P08581 1/20 0.44
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 1/20 0.42
CDC7 O00311 3/20 0.40
ROCK2 O75116 3/20 0.40
PIM1 P11309 3/20 0.40
PRKACA P17612 3/20 0.40
CDK2 P24941 3/20 0.40
GSK3B P49841 3/20 0.40
HIPK2 Q9H2X6 3/20 0.40
IRAK4 Q9NWZ3 3/20 0.40
CDK7 P50613 1/20 0.40
CDK9 P50750 1/20 0.40
MAP4K4 O95819 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
MAP2K1 Q02750 1/20 0.39
HTR1A P08908 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1054756 0.85 CYP2C9 (0.48) FGFR1CYP3A4CYP2C19HTR1ADRD3
SCHEMBL1051963 0.84 GPR84 (0.50) GPR84FGFR1FGFR4METCYP3A4
SCHEMBL411594 0.83 MET (0.56) GPR84FGFR1FGFR4METCYP3A4
SCHEMBL858761 0.83 CYP1A2 (0.50) FGFR1FGFR4CYP3A4CYP2C19CYP1A2
SCHEMBL1054378 0.78 BRAF (0.50) FGFR1FGFR4CYP3A4CDC7ROCK2
SCHEMBL859084 0.76 KIT (0.50) CYP3A4CDK2CDK9CLK4CYP1A2
SCHEMBL415488 0.76 GPR84 (0.47) GPR84FGFR1FGFR4METCYP3A4
SCHEMBL858542 0.76 CYP2C9 (0.48) FGFR1CYP3A4CYP2C19HTR1ADRD3
SCHEMBL415291 0.76 GPR84 (0.50) GPR84FGFR1FGFR4METCYP3A4
SCHEMBL12960761 0.76 CYP2C9 (0.46) CYP3A4CYP2C19HTR1ADRD3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US claimed
US-7872018-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON, INC. (US) 2011-01-18 US disclosed
US-7872018-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON, INC. (US) 2011-01-18 US disclosed
US-7872018-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON, INC. (US) 2011-01-18 US disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221148-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 GPR84 4039/4885FGFR1 775/4885FGFR4 1185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.